BiotechTube
Home/Ovid Therapeutics/Meg Alexander
MA

Meg Alexander

President & Chief Executive Officer

Ovid Therapeutics

Therapeutic Areas

Rare Neurological DiseasesEpilepsyNeurodevelopmental Disorders

Ovid Therapeutics Pipeline

DrugIndicationPhase
OV329Treatment-resistant seizuresPhase 1
OV350Undisclosed CNS disordersPreclinical
OV882SYNGAP1-related intellectual disabilityResearch
OV4071Undisclosed CNS disordersResearch
Soticlestat (OV935/TAK-935)Dravet Syndrome, Lennox-Gastaut SyndromePhase 3

Leadership Team at Ovid Therapeutics

ZZ
Zhong Zhong, Ph.D.
Chief Scientific Officer
TP
Thomas Perone
Chief Legal Officer & Corporate Secretary
RC
R. Cory
SVP, Head of Corporate Affairs & Investor Relations
JM
Jeremy M. Levin, D.Phil, MB BChir
Co-founder and Executive Chairman
JA
Jeffrey A. Chodakewitz, M.D.
Director
RJ
Robert J. Gould, Ph.D.
Director
BD
Barbara Duncan
Director
TD
Timothy Daly
Director
View full Ovid Therapeutics profile